UGN-104

UGN-104 is UroGen Pharma's next-generation mitomycin gel for low-grade upper tract urothelial cancer (UTUC), a rare bladder-cancer cousin that grows in the kidney's collecting system or the ureter rather than the bladder itself [1]. UroGen already sells JELMYTO for this exact indication, a six-week weekly instillation regimen that delivers a complete response in roughly 59% of patients but is hard on both the patient and the urologist threading a catheter into the kidney each week [2][3]. JELMYTO is a meaningful franchise: $87.4M in 2024 net product revenue and $94 to $98M guided for 2025, on $70.2M reported through the first three quarters of 2025 [8]. UGN-104 keeps the same six-week weekly instillation regimen but uses a reformulated mitomycin sourced from medac GmbH that shortens the manufacturing process, simplifies the bedside reconstitution procedure, and resets the IP runway: next-generation product patents extend to December 2041 versus JELMYTO's orphan exclusivity expiring April 15, 2027 and a Teva generic license dated September 15, 2030 [9][10][11]. In other words, the commercial thesis for UGN-104 is operational and IP-driven, not 'fewer doses.' The Phase 3 single-arm registrational trial (NCT06774131) is enrolling 70 patients with complete response rate at approximately 3 months after the first instillation as the primary endpoint, the same design path that won JELMYTO its 2020 approval [1][3][11]. For UroGen, success here defends the UTUC franchise while the company scales ZUSDURI (UGN-102), its newly approved low-grade non-muscle-invasive bladder cancer gel [4].

UGN-104 is Phase 3 and recruiting, sponsored by UroGen, single-arm, target enrollment 70 patients, with complete response rate at the Primary Disease Evaluation visit (approximately 3 months after first instillation) as the primary endpoint [1][11]. No FDA designations have been publicly disclosed for UGN-104 specifically; notably, the predecessor JELMYTO (UGN-101) carried orphan drug, fast track, and breakthrough therapy designations, and the absence of a public orphan designation for UGN-104 is unexplained but may simply reflect that UroGen has not yet sought or disclosed it [2][3]. JELMYTO was approved on the OLYMPUS single-arm n=71 study, so regulatory precedent on the platform is established [2][3]. The regulatory path here looks straightforward in principle: hit a CRR consistent with JELMYTO using the same six-week regimen, then file under a supplemental or new NDA depending on how UroGen positions the formulation. UroGen has not committed publicly to a topline readout date, but management has guided to full enrollment by the end of 2026 [11]. Given a primary endpoint measured roughly 3 months after the first instillation and a target enrollment of 70 patients in a rare-cancer setting, a readout in late 2026 to 2027 is the realistic window. That window is tight against JELMYTO's orphan exclusivity expiring April 15, 2027 [10]. UroGen filed 8-K disclosures on 2025-02-20, 2025-07-03, 2025-08-07, 2025-08-27, and 2026-06-02, which are the natural checkpoints for trial guidance and FDA interactions [5].

Mitomycin C is an old chemotherapy drug, first approved in the 1970s, that works by crosslinking the two strands of DNA inside a cell. Once those strands are glued together, the cell cannot copy its DNA, so when it tries to divide it dies. That works well against tumor cells, which divide constantly, and is hard on healthy tissue exposed to high doses. The harder problem with treating upper tract urothelial cancer is not the drug, it is the plumbing. The renal pelvis and ureter flush urine downward continuously, so any liquid drug instilled into them washes out within minutes, far too fast to kill a tumor. UroGen's reverse thermal gel (RTGel) platform solves the delivery problem. The drug is mixed into a polymer that stays liquid in a cold syringe but turns into a viscous gel at body temperature. A urologist threads a catheter up into the kidney, instills the cold solution, and within minutes it warms and gels in place, holding mitomycin against urothelial tissue for approximately 4 to 6 hours under physiological urine flow before dissolving away [3]. UGN-104 uses the same RTGel platform and the same 4 mg/mL mitomycin dose strength per the trial registration [11]. The clinically relevant point: UGN-104's reformulation does not alter the polymer's thermal behavior or dwell time. The changes are upstream of the patient (a shorter manufacturing process and a simpler bedside reconstitution procedure, using the medac-sourced mitomycin formulation) rather than a different drug-tissue contact profile [9][11].

NCT06774131 is a Phase 3 single-arm open-label study enrolling 70 patients with low-grade UTUC who have papillary tumors amenable to endoscopic ablation. Patients receive UGN-104 once weekly for six weeks (six total instillations), with the primary endpoint of complete response rate assessed at the Primary Disease Evaluation visit approximately three months after the first instillation [1][11]. The design and the six-instillation regimen mirror OLYMPUS, the single-arm n=71 trial that supported JELMYTO's 2020 approval and reported a 59% CRR [2][3]. FDA precedent here is favorable: in low-grade UTUC, a rare disease with no good non-surgical alternatives outside endoscopic ablation or nephroureterectomy, regulators accepted single-arm CRR as the registrational endpoint for the predecessor product. The obvious limitation is that a single-arm trial cannot show superiority over JELMYTO on either efficacy or safety, so UGN-104's commercial pitch will rest on cross-trial comparison of confidence intervals, operational/manufacturing improvements, and durability of response rather than dose-count differentiation. Enrollment of 70 patients in a rare cancer is achievable but historically slow. OLYMPUS took roughly three years to fully enroll across about two dozen sites. UroGen's post-launch UTUC center network, built out for JELMYTO commercial distribution since 2020, is a meaningful enrollment tailwind versus the pre-commercial OLYMPUS era, and pace may outperform the OLYMPUS baseline. Management has guided full enrollment by end of 2026 [11].

Our model estimates a 30% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and smaller-than-typical enrollment for this phase. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

The main efficacy risk is dose-response asymmetry: the reformulated mitomycin in UGN-104 should be bioequivalent at the same 4 mg/mL strength, but the registrational trial is the first test of that in this delivery system at scale [11]. Safety is the more concrete worry. In OLYMPUS, ureteral stenosis, a narrowing of the ureter that can require stenting or surgical repair, occurred in roughly 44% of JELMYTO patients within the first year and was the most common serious adverse event [2]. The toxicity is mechanism-based, so any drift in local exposure with the new formulation could move the rate. If stenosis runs at 60% or above in the UGN-104 trial, both the regulatory calculus and the commercial pitch change. Execution risk is real: UroGen received a complete response letter for UGN-102 in May 2024 over chemistry, manufacturing, controls, and dosing-strength questions before securing approval in June 2025 as ZUSDURI [4][7]. The same scrutiny could land on a reformulated UGN-104 supply chain. Timing risk is the underappreciated one: JELMYTO's 7-year orphan exclusivity expires April 15, 2027 [10]. A late-2026 to 2027 readout followed by typical NDA review could push UGN-104 approval past the cliff, leaving UroGen defending a premium-priced successor against a genericized predecessor (Teva is licensed from September 15, 2030, and other ANDA filers could arrive earlier post-exclusivity) [10]. Commercial risk centers on cannibalization. If UGN-104 prices at parity with JELMYTO and largely replaces it, UroGen needs payer acceptance for a formulary swap. If priced as a premium product without head-to-head superiority data, payers will push back. The bear case is a clean trial that shifts existing JELMYTO patients rather than expanding the addressable population.

Worth watching, with two data points that decide the story. First, ureteral stenosis incidence in the safety section of the readout: if UGN-104 delivers a CRR within a few points of JELMYTO's 59% and stenosis stays at or below the 44% OLYMPUS rate, this is a clean win and the UTUC franchise extends. If stenosis runs materially higher, the commercial case collapses regardless of response rate. Second, the readout date against the April 15, 2027 orphan exclusivity cliff [10]: a readout in late 2026 with a fast supplemental NDA review buys UroGen continuous exclusivity into the next-generation IP runway (patents to December 2041) [9]; a 2027 readout followed by a standard NDA cycle risks an approval window that opens after the cliff, leaving a genericized JELMYTO as the de facto competitor. UroGen's post-launch UTUC site network is a real enrollment tailwind versus OLYMPUS-era expectations and is the structural reason a late-2026 readout is plausible. UroGen is the most interesting pure-play genitourinary specialty pharma on the board, with JELMYTO running at a roughly $94 to $98M annual run-rate in 2025 [8], ZUSDURI in early commercial launch, and a Phase 3 readout ahead. UGN-104 protects the back end of the UTUC franchise and gives the company a multi-asset story rather than a single-product one. Check back when UroGen issues a primary completion date update in an 8-K or earnings call, when interim safety data shows up at AUA or ASCO GU, or when UroGen confirms or denies orphan designation for UGN-104 specifically [5].